5,6-difluoro-4-[2-(2-thienyl)ethynyl]-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 5,6-difluoro-4-[2-(2-thienyl)ethynyl]-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
• 英文别名: 5,6-difluoro-4-(2-thiophen-2-ylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
• 化学式: C₁₅H₆F₅NO₂S
• 分子量: 359.276
• InChiKey: IVYSIAURPZMBOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  66.6
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  邻氨基三氟甲基酮 在 正丁基锂 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 1.0h， 生成 5,6-difluoro-4-[2-(2-thienyl)ethynyl]-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
  参考文献：
  名称：

  Synthesis and Evaluation of Efavirenz (SustivaTM) Analogues as HIV-1 Reverse Transcriptase Inhibitors: Replacement of the Cyclopropylacetylene Side Chain

  摘要：

  Two series of efavirenz analogues have been developed: one in which the cyclopropane ring has been replaced by small heterocycles and another in which the entire acetylenic side chain has been replaced by alkyloxy groups. Several members of both series show equivalent potency to efavirenz against both wild-type virus and the key K103N mutant. (C) 2001 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00192-5

文献信息

• Synthesis and Evaluation of Efavirenz (SustivaTM) Analogues as HIV-1 Reverse Transcriptase Inhibitors: Replacement of the Cyclopropylacetylene Side Chain
  作者：Anthony J. Cocuzza、Dennis R. Chidester、Beverly C. Cordova、Susan Jeffrey、Rodney L. Parsons、Lee T. Bacheler、Susan Erickson-Viitanen、George L. Trainor、Soo S. Ko

  DOI：10.1016/s0960-894x(01)00192-5

  日期：2001.5

  Two series of efavirenz analogues have been developed: one in which the cyclopropane ring has been replaced by small heterocycles and another in which the entire acetylenic side chain has been replaced by alkyloxy groups. Several members of both series show equivalent potency to efavirenz against both wild-type virus and the key K103N mutant. (C) 2001 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.